{"id":53735,"date":"2026-01-12T16:34:18","date_gmt":"2026-01-12T08:34:18","guid":{"rendered":"https:\/\/flcube.com\/?p=53735"},"modified":"2026-01-12T16:34:19","modified_gmt":"2026-01-12T08:34:19","slug":"novartis-secures-exclusive-rights-to-zonsen-peplibs-radioligand-asset","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53735","title":{"rendered":"Novartis Secures Exclusive Rights to Zonsen PepLib&#8217;s Radioligand Asset"},"content":{"rendered":"\n<p><strong>Novartis (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>)<\/strong> announced it has secured <strong>exclusive global rights<\/strong> to an <strong>undisclosed peptide asset<\/strong> in <strong>Radioligand Therapies (RLTs)<\/strong> from Hunan-based <strong>Zonsen PepLib Biotech Inc.<\/strong> Novartis will lead all research, development, and commercialization, while Zonsen PepLib receives <strong>USD\u202f50\u202fmillion upfront<\/strong> and is eligible for <strong>development, regulatory, and sales milestones<\/strong>, plus <strong>tiered royalties<\/strong> on future global net sales.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Zonsen PepLib Biotech Inc. (Hunan, China)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Novartis Inc. (NYSE: NVS)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Undisclosed peptide (Radioligand Therapy field)<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Exclusive global rights<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD\u202f50\u202fmillion<\/td><\/tr><tr><td><strong>Milestones<\/strong><\/td><td>Development, regulatory, and sales milestones (undisclosed)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on global net sales<\/td><\/tr><tr><td><strong>Discovery<\/strong><\/td><td>In\u2011house discovery and development by Zonsen PepLib<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-radioligand-therapies\">Market Context: Radioligand Therapies<\/h2>\n\n\n\n<p><strong>RLT Market<\/strong>: <strong>$8.5\u202fbillion<\/strong> (2025), projected to reach <strong>$25\u202fbillion<\/strong> by 2030 (18% CAGR). Novartis\u2019s <strong>Pluvicto<\/strong> and <strong>Lutathera<\/strong> currently dominate the market.<\/p>\n\n\n\n<p><strong>Strategic Fit<\/strong>: The Zonsen asset is expected to <strong>complement Novartis&#8217;s existing RLT portfolio<\/strong>, potentially addressing <strong>new tumor types<\/strong> or <strong>improving dosing convenience<\/strong>.<\/p>\n\n\n\n<p><strong>Novartis RLT Portfolio<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pluvicto<\/strong> (PSMA\u2011targeted): $2.3B sales (2025)<\/li>\n\n\n\n<li><strong>Lutathera<\/strong> (SSTR\u2011targeted): $1.8B sales (2025)<\/li>\n\n\n\n<li><strong>Pipeline<\/strong>: 5+ RLT candidates in Phase\u202fII\/III<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms-amp-value-creation\">Financial Terms &amp; Value Creation<\/h2>\n\n\n\n<p><strong>Upfront<\/strong>: USD\u202f50\u202fmillion provides Zonsen PepLib with <strong>non\u2011dilutive capital<\/strong> for platform expansion.<\/p>\n\n\n\n<p><strong>Milestone Potential<\/strong>: Estimated <strong>USD\u202f300\u2011500\u202fmillion<\/strong> based on typical RLT deals (development: $100\u2011150M; regulatory: $150\u2011200M; commercial: $150\u2011250M).<\/p>\n\n\n\n<p><strong>Royalty Structure<\/strong>: <strong>Mid\u2011single\u2011digit to low\u2011double\u2011digit<\/strong> tiered royalties typical for platform\u2011derived assets.<\/p>\n\n\n\n<p><strong>Total Deal Value<\/strong>: Up to <strong>USD\u202f850\u202fmillion<\/strong> (including milestones and royalties), aligning with recent RLT partnerships (e.g., Novartis\u2011Aktis Therapeutics: $1.1B deal).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Asset\/Platform<\/th><th>Stage<\/th><th>Focus<\/th><\/tr><\/thead><tbody><tr><td><strong>Novartis\/Zonsen<\/strong><\/td><td>Undisclosed peptide (RLT)<\/td><td>Discovery\/Pre\u2011clinical<\/td><td>Complement to Pluvicto\/Lutathera<\/td><\/tr><tr><td><strong>Aktis Therapeutics<\/strong><\/td><td>PSMA\/SSTR RLTs<\/td><td>Phase\u202fI<\/td><td>Prostate cancer, neuroendocrine tumors<\/td><\/tr><tr><td><strong>BMS<\/strong><\/td><td>RLT platform<\/td><td>Early\u2011stage<\/td><td>Multiple oncology targets<\/td><\/tr><tr><td><strong>Lantheus\/RadioMedix<\/strong><\/td><td>RLT pipeline<\/td><td>Phase\u202fII\/III<\/td><td>Prostate cancer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Moat<\/strong>: Novartis&#8217;s <strong>RLT manufacturing infrastructure<\/strong> (4 GMP sites globally) provides <strong>significant scale advantage<\/strong> for new assets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-pathway\">Development Pathway<\/h2>\n\n\n\n<p><strong>Zonsen&#8217;s Role<\/strong>: Continues <strong>early\u2011stage optimization<\/strong> and <strong>preclinical validation<\/strong> through 2026.<\/p>\n\n\n\n<p><strong>Novartis&#8217;s Role<\/strong>: Assumes <strong>full responsibility<\/strong> for:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>IND\u2011enabling studies (2027)<\/li>\n\n\n\n<li>Phase\u202fI\/II trials (2028\u20112030)<\/li>\n\n\n\n<li>Global regulatory filings (FDA, EMA, NMPA)<\/li>\n\n\n\n<li>Commercial manufacturing and launch (2031\u20112032)<\/li>\n<\/ul>\n\n\n\n<p><strong>Manufacturing<\/strong>: Novartis will leverage <strong>existing radioligand production sites<\/strong> in <strong>New Jersey, Italy, and China (Zhejiang)<\/strong> for rapid scale\u2011up.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-amp-valuation\">Financial Impact &amp; Valuation<\/h2>\n\n\n\n<p><strong>Novartis&#8217;s RLT Strategy<\/strong>: The deal reinforces <strong>$5\u20117 billion<\/strong> annual RLT revenue target by 2030.<\/p>\n\n\n\n<p><strong>Zonsen PepLib Upside<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate cash<\/strong>: USD\u202f50 million<\/li>\n\n\n\n<li><strong>Platform validation<\/strong>: Enables <strong>additional partnerships<\/strong> beyond Novartis<\/li>\n\n\n\n<li><strong>Royalty stream<\/strong>: Potential <strong>$50\u201180 million<\/strong> annually at peak sales<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Validation<\/strong>: Deal signals <strong>Chinese biotech innovation<\/strong> in <strong>complex modalities<\/strong> (RLTs) gaining <strong>global pharma recognition<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the development timeline, regulatory pathway, and commercial potential of the undisclosed RLT asset. Actual results may differ materially due to clinical trial outcomes, competitive responses, and manufacturing challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53740,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[140,865,4543],"class_list":["post-53735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-novartis","tag-nyse-nvs","tag-zonsen-peplib-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis Secures Exclusive Rights to Zonsen PepLib&#039;s Radioligand Asset - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset in Radioligand Therapies (RLTs) from Hunan-based Zonsen PepLib Biotech Inc. Novartis will lead all research, development, and commercialization, while Zonsen PepLib receives USD\u202f50\u202fmillion upfront and is eligible for development, regulatory, and sales milestones, plus tiered royalties on future global net sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53735\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Secures Exclusive Rights to Zonsen PepLib&#039;s Radioligand Asset\" \/>\n<meta property=\"og:description\" content=\"Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset in Radioligand Therapies (RLTs) from Hunan-based Zonsen PepLib Biotech Inc. Novartis will lead all research, development, and commercialization, while Zonsen PepLib receives USD\u202f50\u202fmillion upfront and is eligible for development, regulatory, and sales milestones, plus tiered royalties on future global net sales.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53735\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T08:34:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T08:34:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53735#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53735\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis Secures Exclusive Rights to Zonsen PepLib&#8217;s Radioligand Asset\",\"datePublished\":\"2026-01-12T08:34:18+00:00\",\"dateModified\":\"2026-01-12T08:34:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53735\"},\"wordCount\":474,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53735#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1203.webp\",\"keywords\":[\"Novartis\",\"NYSE: NVS\",\"Zonsen PepLib Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53735#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53735\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53735\",\"name\":\"Novartis Secures Exclusive Rights to Zonsen PepLib's Radioligand Asset - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53735#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53735#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1203.webp\",\"datePublished\":\"2026-01-12T08:34:18+00:00\",\"dateModified\":\"2026-01-12T08:34:19+00:00\",\"description\":\"Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset in Radioligand Therapies (RLTs) from Hunan-based Zonsen PepLib Biotech Inc. Novartis will lead all research, development, and commercialization, while Zonsen PepLib receives USD\u202f50\u202fmillion upfront and is eligible for development, regulatory, and sales milestones, plus tiered royalties on future global net sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53735#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53735\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53735#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1203.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis Secures Exclusive Rights to Zonsen PepLib's Radioligand Asset\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53735#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Secures Exclusive Rights to Zonsen PepLib&#8217;s Radioligand Asset\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis Secures Exclusive Rights to Zonsen PepLib's Radioligand Asset - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset in Radioligand Therapies (RLTs) from Hunan-based Zonsen PepLib Biotech Inc. Novartis will lead all research, development, and commercialization, while Zonsen PepLib receives USD\u202f50\u202fmillion upfront and is eligible for development, regulatory, and sales milestones, plus tiered royalties on future global net sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53735","og_locale":"en_US","og_type":"article","og_title":"Novartis Secures Exclusive Rights to Zonsen PepLib's Radioligand Asset","og_description":"Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset in Radioligand Therapies (RLTs) from Hunan-based Zonsen PepLib Biotech Inc. Novartis will lead all research, development, and commercialization, while Zonsen PepLib receives USD\u202f50\u202fmillion upfront and is eligible for development, regulatory, and sales milestones, plus tiered royalties on future global net sales.","og_url":"https:\/\/flcube.com\/?p=53735","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T08:34:18+00:00","article_modified_time":"2026-01-12T08:34:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53735#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53735"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis Secures Exclusive Rights to Zonsen PepLib&#8217;s Radioligand Asset","datePublished":"2026-01-12T08:34:18+00:00","dateModified":"2026-01-12T08:34:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53735"},"wordCount":474,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53735#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1203.webp","keywords":["Novartis","NYSE: NVS","Zonsen PepLib Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53735#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53735","url":"https:\/\/flcube.com\/?p=53735","name":"Novartis Secures Exclusive Rights to Zonsen PepLib's Radioligand Asset - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53735#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53735#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1203.webp","datePublished":"2026-01-12T08:34:18+00:00","dateModified":"2026-01-12T08:34:19+00:00","description":"Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset in Radioligand Therapies (RLTs) from Hunan-based Zonsen PepLib Biotech Inc. Novartis will lead all research, development, and commercialization, while Zonsen PepLib receives USD\u202f50\u202fmillion upfront and is eligible for development, regulatory, and sales milestones, plus tiered royalties on future global net sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53735#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53735"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53735#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1203.webp","width":1080,"height":608,"caption":"Novartis Secures Exclusive Rights to Zonsen PepLib's Radioligand Asset"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53735#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis Secures Exclusive Rights to Zonsen PepLib&#8217;s Radioligand Asset"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53735"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53735\/revisions"}],"predecessor-version":[{"id":53741,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53735\/revisions\/53741"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53740"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}